SG Americas Securities LLC Increases Position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

SG Americas Securities LLC grew its holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 107.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,090 shares of the biopharmaceutical company’s stock after purchasing an additional 23,893 shares during the quarter. SG Americas Securities LLC’s holdings in Lexicon Pharmaceuticals were worth $72,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Nantahala Capital Management LLC purchased a new position in Lexicon Pharmaceuticals during the second quarter worth approximately $3,871,000. Point72 Asset Management L.P. boosted its position in shares of Lexicon Pharmaceuticals by 605.2% during the 2nd quarter. Point72 Asset Management L.P. now owns 4,121,191 shares of the biopharmaceutical company’s stock valued at $6,924,000 after acquiring an additional 3,536,805 shares during the last quarter. CVI Holdings LLC acquired a new position in shares of Lexicon Pharmaceuticals during the 2nd quarter valued at about $34,000. The Manufacturers Life Insurance Company grew its holdings in shares of Lexicon Pharmaceuticals by 40.5% in the second quarter. The Manufacturers Life Insurance Company now owns 49,957 shares of the biopharmaceutical company’s stock valued at $84,000 after purchasing an additional 14,411 shares during the period. Finally, Great Point Partners LLC acquired a new stake in Lexicon Pharmaceuticals during the second quarter worth about $50,000. 74.70% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on LXRX. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Lexicon Pharmaceuticals in a report on Wednesday, October 23rd. StockNews.com upgraded Lexicon Pharmaceuticals to a “sell” rating in a report on Tuesday, July 9th. Finally, Leerink Partners set a $6.00 target price on Lexicon Pharmaceuticals and gave the stock an “outperform” rating in a research note on Friday, October 18th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, Lexicon Pharmaceuticals has an average rating of “Hold” and an average price target of $8.00.

Lexicon Pharmaceuticals Price Performance

Lexicon Pharmaceuticals stock opened at $1.86 on Tuesday. The company’s 50 day simple moving average is $1.72 and its 200-day simple moving average is $1.76. The company has a debt-to-equity ratio of 0.41, a quick ratio of 11.49 and a current ratio of 11.51. Lexicon Pharmaceuticals, Inc. has a 1 year low of $0.92 and a 1 year high of $3.73. The company has a market capitalization of $458.00 million, a price-to-earnings ratio of -2.24 and a beta of 1.28.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.01. Lexicon Pharmaceuticals had a negative return on equity of 105.38% and a negative net margin of 5,509.34%. The company had revenue of $1.65 million for the quarter, compared to analyst estimates of $2.74 million. During the same quarter in the previous year, the company earned ($0.22) earnings per share. As a group, equities research analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.69 earnings per share for the current year.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.